Although the effect of SVR to IFN-free therapy on HCC occurrence was controversial in earlier studies due to the older age and more advanced fibrosis among patients receiving IFN-free therapy35,36, later studies suggested that SVR to IFN-free therapy did in fact reduce the risk of HCC37. The gene discussed is IFNA1; the disease is hepatocellular carcinoma.